Open AccessAssessment of the application for renewal of authorisation of AveMix ® XG 10 (endo‐1,4‐beta‐xylanase and endo‐1,3(4)‐beta‐glucanase) for chickens for fattening
Author(s) -
Bampidis Vasileios,
Azimonti Giovanna,
Bastos Maria de Lourdes,
Christensen Henrik,
Dusemund Birgit,
Kos Durjava Mojca,
Kouba Maryline,
LópezAlonso Marta,
López Puente Secundino,
Marcon Francesca,
Mayo Baltasar,
Pechová Alena,
Petkova Mariana,
Ramos Fernando,
Sanz Yolanda,
Villa Roberto Edoardo,
Woutersen Ruud,
Cocconcelli Pier Sandro,
Glandorf Boet,
Herman Lieve,
Maradona Prieto Miguel,
Saarela Maria,
Brozzi Rosella,
Galobart Jaume,
Innocenti Matteo,
LópezGálvez Gloria,
Sofianidis Konstantinos,
Vettori Maria Vittoria,
Gregoretti Lucilla,
Mayo Baltasar
Publication year - 2020
Publication title -
efsa journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.076
H-Index - 97
ISSN - 1831-4732
DOI - 10.2903/j.efsa.2020.6062
Subject(s) - authorization , context (archaeology) , european commission , medicine , food science , microbiology and biotechnology , business , biology , european union , computer science , paleontology , computer security , economic policy
Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed ( FEEDAP ) was asked to deliver a scientific opinion on the assessment of the application for renewal of authorisation of AveMix ® XG 10 (endo‐1,4‐beta‐xylanase and endo‐1,3(4)‐beta‐glucanase) for chickens for fattening. The applicant has provided evidence that the additive currently in the market complies with the existing conditions of authorisation. There is no new evidence that would lead the FEEDAP Panel to reconsider its previous conclusions. Thus, the Panel concludes that the additive remains safe for the target species, consumer and the environment under the authorised conditions of use. Regarding user safety, the additive is not considered to be a dermal or eye irritant but it is a dermal and respiratory sensitiser. There is no need for assessing the efficacy of the additive in the context of the renewal of the authorisation.